Clinical Trials

We are dedicated to safely providing new treatment options to patients in need.

Enrollment in one of our clinical trials is our primary method for providing patients with access to our investigational drugs prior to their potential approval by regulatory authorities, including the United States Food and Drug Administration, and subsequent commercial availability. Clinical trials are required to demonstrate that an investigational drug meets safety and efficacy standards necessary for approval by regulatory authorities.

To participate in one of our clinical trials, you and your disease must meet specific criteria. As participation in a clinical trial comes with risks, you must also provide your “informed consent” prior to enrolling in a clinical trial.

Our goal is to ensure that appropriate patients can access our investigational drugs at the appropriate time and in the correct manner. We encourage participation in clinical trials and believe that participating in a clinical trial is the best way for patients to access our investigational drugs prior to regulatory approval.

Indication Program Study Information
Selected advanced cancers Cabiralizumab (FPA008)

Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)

Learn more

Advanced pancreatic cancer Cabiralizumab (FPA008)

Cabiralizumab Given With Nivolumab and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Learn more

Pigmented Villonodular Synovitis Cabiralizumab (FPA008)

Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor (FPA008-002)

Learn more

Advanced solid tumors Bemarituzumab (FPA144)

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients with Advanced Solid Tumors

Learn more

Gastric / gastroesophageal cancer

Bemarituzumab (FPA144)

FPA144 Combined with Modified FOLFOX6 in Gastric / Gastroesophageal Cancer (FIGHT)

Learn more

Advanced solid tumors FPA150

FPA150 in Patients with Advanced Solid Tumors (FPA150-001)

Learn More